Comprehensive analysis of Japanese nationwide cohort data of particle beam therapy for pulmonary, liver and lymph node oligometastases: particle beam therapy versus high-precision X-ray radiotherapy
Authors:
Open Access
- 13 April 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 64 (Supplement) , i69-i83
Abstract
Japanese national oncological experts convened to evaluate the efficacy and safety of particle beam therapy (PT) for pulmonary, liver and lymph node oligometastases (P-OM, L-OM and LN-OM, respectively) and to conduct a statistically comparative analysis of the local control (LC) rate and overall survival (OS) rate of PT versus those of X-ray stereotactic body radiotherapy (X-SBRT) and X-ray intensity-modulated radiotherapy (X-IMRT). They conducted [1] an analysis of the efficacy and safety of metastasis-directed therapy with PT for P-OM, L-OM and LN-OM using a Japanese nationwide multi-institutional cohort study data set; [2] a systematic review of X-ray high-precision radiotherapy (i.e. X-SBRT/X-IMRT) and PT for P-OM, L-OM and LN-OM; and [3] a statistical comparison between LC and OS of the cohort data set in PT and that of the extracted historical data set in X-SBRT/X-IMRT from the preceding systematic review. Safety was evaluated as the incidence of grade ≥ 3 adverse events, while statistical comparisons of LC and OS were conducted by estimating the incidence rate ratios (IRR) for local progression and mortality, respectively. This study demonstrated that PT provided durable LC (3-year LC rate: 72.8–83.2%) with acceptable OS (3-year OS rate: 38.5–68.1%) and risk of severe toxicity incidence of 0.8–3.5% in radical metastasis-directed therapy for P-OM, L-OM and LN-OM. Compared to LC with X-SBRT or X-IMRT, LC with PT was potentially superior for P-OM; superior for L-OM; and equivalent for LN-OM. In particular, this study demonstrated that PT may be a new treatment option for L-OM tumors measuring > 5 cm.Keywords
Funding Information
- Hokkaido University and AMED (JP16lm0103004)
- National Institutes for Quantum Science and Technology
- Japan Society for the Promotion of Science (JP 20 K16797)
This publication has 53 references indexed in Scilit:
- Linac-based Stereotactic Body Radiotherapy for Oligometastatic Patients With Single Abdominal Lymph Node Recurrent CancerAmerican Journal of Clinical Oncology, 2014
- Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patientsRadiation Oncology, 2014
- Carbon ion radiotherapy for oligo-recurrent lung metastases from colorectal cancer: a feasibility studyRadiation Oncology, 2014
- Is Stereotactic Body Radiation Therapy an Attractive Option for Unresectable Liver Metastases? A Preliminary Report From a Phase 2 TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Carbon Ion Radiotherapy for Oligo-Recurrence in the LungPulmonary Medicine, 2013
- High dose stereotactic body radiotherapy using three fractions for colorectal oligometastasesJournal of Surgical Oncology, 2012
- Oligometastases revisitedNature Reviews Clinical Oncology, 2011
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLOS Medicine, 2009
- Image-Guided Stereotactic Body Radiation Therapy in Patients With Isolated Para-Aortic Lymph Node Metastases From Uterine Cervical and Corpus CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Interim analysis of a prospective phase I/II trial of SBRT for liver metastasesActa Oncologica, 2006